This is a paid press release. Contact the press release distributor directly with any inquiries.
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
INmune Bio, Inc.
Mon, July 20, 2026 at 4:30 PM GMT+5:30
5 min read
- INMB
+6.58%
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply
Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework
BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult (CGT Catapult) Manufacturing Innovation Centre in Stevenage, UK, under its commercial agreement with Anthony Nolan Cord Blood Bank.
This achievement marks the successful transfer of the mesenchymal stromal cell (MSC) isolation stage for the manufacture of master cell banks (MCBs) into INmune Bio’s commercial manufacturing facility. The process is now commercial-ready to MHRA, EMA and FDA standards, including maternal blood samples infectious disease testing in US-CLIA-accredited laboratories. The successful technology transfer positions the Company to generate its first US tested master cell banks for Ebstrocel™, the RDEB-specific investigational product derived from the CORDStrom™ platform, in support of its planned Phase 3 confirmation clinical trial and future commercial supply.
“Completing this manufacturing transfer is one of the most important operational milestones for the CORDStrom platform. We now have the manufacturing infrastructure required to generate master cell banks that support our planned Phase 3 program and future commercial production using a process designed to satisfy both UK and U.S. regulatory expectations. I am hugely proud of the team for getting to this milestone so quickly,” said Professor Mark W. Lowdell, PhD, FRCPath, FRSB, Chief Scientific Officer of INmune Bio.
“This important milestone reflects the strength of collaboration between Anthony Nolan, the Cell and Gene Therapy Catapult, and INmune Bio, and marks another critical step towards commercial delivery of Ebstrocel™,” said Dr. Ben Weil, MBA, EngD, Head of UK Operations at INmune Bio. “Everyone involved in the CORDStrom™ platform understands the urgency and criticality of developing potentially life-changing medicines to children living with RDEB and other rare diseases. Building a reliable, scalable, and commercial ready manufacturing platform is only possible through the commitment and expertise of all our suppliers and service partners.”
